Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy?

被引：25

作者：

Insa, Amelia ^{[1
]}

Martin-Martorell, Paloma ^{[1
]}

Di Liello, Raimondo ^{[2
]}

Fasano, Morena ^{[2
]}

Martini, Giulia ^{[2
]}

Napolitano, Stefania ^{[2
]}

Vicidomini, Giovanni ^{[3
]}

Cappabianca, Salvatore ^{[4
]}

Franco, Renato ^{[5
]}

Morgillo, Floriana ^{[2
]}

Della Corte, Carminia Maria ^{[2
]}

机构：

[1] Hosp Clin Univ Valencia, Med Oncol Dept, Valencia 46010, Spain

[2] Univ Campania Luigi Vanvitelli, Dept Precis Med, Med Oncol, Via Sergio Pansini 5, I-80131 Naples, Italy

[3] Univ Campania Luigi Vanvitelli, Dept Translat Med Sci, Thorac Surg Unit, I-80131 Naples, Italy

[4] Univ Campania Luigi Vanvitelli, Radiol, Dept Precis Med, I-80131 Naples, Italy

[5] Univ Campania Luigi Vanvitelli, Dept Expt Med, Pathol Unit, I-80131 Naples, Italy

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2022年 / 169卷

关键词：

Immunotherapy; Chemotherapy; Second line therapy; NSCLC; ICI resistance; CELL LUNG-CANCER; IMMUNE CHECKPOINT INHIBITORS; NIVOLUMAB PLUS IPILIMUMAB; PHASE-III; PD-L1; EXPRESSION; OPEN-LABEL; CHEMOTHERAPY CHEMO; 1ST-LINE NIVOLUMAB; PATIENTS PTS; PEMBROLIZUMAB;

D O I：

10.1016/j.critrevonc.2021.103538

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cancer immunotherapy has produced an unprecedented durable response rate, thus shifting from traditional doublet chemotherapy to immunotherapy-based treatments with and without chemotherapy as the first line strategies for advanced non-small cell lung cancer patients without a molecular driver. However, the majority of patients do not benefit from the treatment or may relapse after a period of response. As few treatment options are available after failure of cancer immunotherapy, including the combination of chemotherapy and antiangiogenic drugs, a better understanding of the mechanisms limiting cancer immunotherapy may be of help in the definition of the best second line. Whereas only retrospective data support an immunotherapy rechallenge approach, new combination strategies including immunotherapy and cell-signaling inhibitors or double immunotherapy represent the newest and most promising strategy to overcome primary or acquired resistance to first line immunotherapy.

引用

页数：10

共 88 条

[51] HGF/MET and the Immune System: Relevance for Cancer Immunotherapy [J].

Papaccio, Federica ;

Della Corte, Carminia Maria ;

Viscardi, Giuseppe ;

Di Liello, Raimondo ;

Esposito, Giovanna ;

Sparano, Francesca ;

Ciardiello, Fortunato ;

Morgillo, Floriana .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (11)

[52] Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma [J].

Parra, Edwin R. ;

Villalobos, Pamela ;

Mino, Barbara ;

Rodriguez-Canales, Jaime .

APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2018, 26 (02) :83-93

[53] Use of Multi-Site Radiation Therapy for Systemic Disease Control [J].

Patel, Roshal R. ;

Verma, Vivek ;

Barsoumian, Hampartsoum B. ;

Matthew, S. ;

Chun, Stephen G. ;

Tang, Chad ;

Chang, Joe Y. ;

Lee, Percy P. ;

Balter, Peter ;

Dunn, Joe Dan ;

Chen, Dawei ;

Puebla-Osorio, Nahum ;

Angelica, Maria ;

Welsh, James W. .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 109 (02) :352-364

[54] Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer [J].

Paz-Ares, L. ;

Luft, A. ;

Vicente, D. ;

Tafreshi, A. ;

Gumus, M. ;

Mazieres, J. ;

Hermes, B. ;

Senler, F. Cay ;

Csoszi, T. ;

Fulop, A. ;

Rodriguez-Cid, J. ;

Wilson, J. ;

Sugawara, S. ;

Kato, T. ;

Lee, K. H. ;

Cheng, Y. ;

Novello, S. ;

Halmos, B. ;

Li, X. ;

Lubiniecki, G. M. ;

Piperdi, B. ;

Kowalski, D. M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (21) :2040-2051

[55] First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial [J].

Paz-Ares, Luis ;

Ciuleanu, Tudor-Eliade ;

Cobo, Manuel ;

Schenker, Michael ;

Zurawski, Bogdan ;

Menezes, Juliana ;

Richardet, Eduardo ;

Bennouna, Jaafar ;

Felip, Enriqueta ;

Juan-Vidal, Oscar ;

Alexandru, Aurelia ;

Sakai, Hiroshi ;

Lingua, Alejo ;

Salman, Pamela ;

Souquet, Pierre-Jean ;

De Marchi, Pedro ;

Martin, Claudio ;

Perol, Maurice ;

Scherpereel, Arnaud ;

Lu, Shue ;

John, Thomas ;

Carbone, David P. ;

Meadows-Shropshire, Stephanie ;

Agrawal, Shruti ;

Oukessou, Abderrahim ;

Yan, Jinchun ;

Reck, Martin .

LANCET ONCOLOGY, 2021, 22 (02) :198-211

[56] A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407 [J].

Paz-Ares, Luis ;

Vicente, David ;

Tafreshi, Ali ;

Robinson, Andrew ;

Parra, Hector Soto ;

Mazieres, Julien ;

Hermes, Barbara ;

Cicin, Irfan ;

Medgyasszay, Balazs ;

Rodriguez-Cid, Jeronimo ;

Okamoto, Isamu ;

Lee, SungSook ;

Ramlau, Rodryg ;

Vladimirov, Vladimir ;

Cheng, Ying ;

Deng, Xuan ;

Zhang, Ying ;

Bas, Tuba ;

Piperdi, Bilal ;

Halmos, Balazs .

JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (10) :1657-1669

[57] Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers [J].

Peng, David H. ;

Rodriguez, B. Leticia ;

Diao, Lixia ;

Gaudreau, Pierre-Olivier ;

Padhye, Aparna ;

Konen, Jessica M. ;

Ochieng, Joshua K. ;

Class, Caleb A. ;

Fradette, Jared J. ;

Gibson, Laura ;

Chen, Limo ;

Wang, Jing ;

Byers, Lauren A. ;

Gibbons, Don L. .

NATURE COMMUNICATIONS, 2021, 12 (01)

[58] VP2-2021: Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small cell lung cancer (Nsq-NSCLC) with high PD-L1 expression using real-world data [J].

Peters, S. ;

Dafni, U. ;

Perol, M. ;

Felip, E. ;

Polito, L. ;

Pal, N. ;

Ton, T. G. N. ;

Merritt, D. ;

Morris, S. ;

Stahel, R. A. .

ANNALS OF ONCOLOGY, 2021, 32 (05) :687-688

[59] Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Planchard, D. ;

Popat, S. ;

Kerr, K. ;

Novello, S. ;

Smit, E. F. ;

Faivre-Finn, C. ;

Mok, T. S. ;

Reck, M. ;

Van Schil, P. E. ;

Hellmann, M. D. ;

Peters, S. .

ANNALS OF ONCOLOGY, 2018, 29 :192-237

[60] Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer? [J].

Popat, Sanjay ;

Grohe, Christian ;

Corral, Jesus ;

Reck, Martin ;

Novello, Silvia ;

Gottfried, Maya ;

Radonjic, Dejan ;

Kaiser, Rolf .

LUNG CANCER, 2020, 144 :76-84

← 1 2 3 4 5 6 7 8 9 →